Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approval request, ICER and Verdant Research publish a new white paper examining the evolution and future of the FDA's accelerated approval pathway, and a new Pharmaceutical Executive commentary argues FDA's shift toward single-trial approval standards marks the beginning of a genuinely new era in data-driven drug development.

Eli Lilly has published updated safety data for Foundayo, in response to a post-approval letter from the FDA asking for additional evidence on potential cardiovascular and liver safety risks. The agency's letter, signed on the day of approval, cited concerns about drug-induced liver injury, major adverse cardiovascular events, and delayed gastric emptying, and required clinical trial data rather than observational studies to address them. Lilly responded by releasing topline results from its Phase III Achieve-4 trial, the largest and longest Foundayo study in type 2 diabetes.

ICER and Verdant Research have published a new white paper titled "Strengthening the FDA's Accelerated Approval Pathway: Progress and Unfinished Business," examining how the pathway has evolved since its 1992 origins and what reforms remain necessary to better balance early patient access against the need for confirmatory evidence. The paper reviews recent regulatory and market changes, including the FDA's more active use of withdrawal authority, and proposes policy options for regulators, payers, and manufacturers focused on tightening surrogate endpoint selection, enforcing confirmatory trial timelines, and improving transparency around drugs that remain on the market under conditional approval for extended periods.

Finally, a new commentary in Pharmaceutical Executive argues that the FDA's recent shift to a single-trial default for drug approvals signals a deeper structural transition in how the industry will need to think about evidence generation. The author argues the change is not a loosening of standards but a recognition that two poorly designed trials do not guarantee validity, and that advances in data infrastructure, AI, and real-world data networks now make it possible to generate regulatory-grade confirmatory evidence more efficiently.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.